Philippe J Zamor
Overview
Explore the profile of Philippe J Zamor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ludden T, Shade L, Thomas J, Russo M, Leonard M, Zamor P, et al.
J Am Board Fam Med
. 2022 Oct;
35(5):990-997.
PMID: 36257701
Introduction: Increased screening efforts and the development of effective antiviral treatments have led to marked improvement in Hepatitis C (HCV) patient outcomes. However, many people in the US are believed...
2.
Zamor P, Lane A
Clin Liver Dis
. 2021 Oct;
25(4):689-709.
PMID: 34593148
Hepatitis B was discovered by researchers who were investigating jaundice associated with blood transfusions as well as parenterally administered medications. Through trial and error, the HBV was identified. There are...
3.
Zamor P, Brown A, Dylla D, Dillon J, Luetkemeyer A, Feld J, et al.
Am J Gastroenterol
. 2021 Sep;
116(9):1896-1904.
PMID: 34465693
Introduction: Pangenotypic, all-oral direct-acting antivirals, such as glecaprevir/pibrentasvir (G/P), are recommended for treatment of hepatitis C virus (HCV) infection. Concerns exist about the impact on efficacy in patients with suboptimal...
4.
Ludden T, Shade L, Thomas J, Urquieta de Hernandez B, Mohanan S, Russo M, et al.
J Am Board Fam Med
. 2020 May;
33(3):407-416.
PMID: 32430372
Background: Increased screening efforts and the development of effective antiviral treatments have led to marked improvement in hepatitis C (HCV) patient outcomes. However, many people in the United States are...
5.
Lawitz E, Flisiak R, Abunimeh M, Sise M, Park J, Kaskas M, et al.
Liver Int
. 2019 Dec;
40(5):1032-1041.
PMID: 31821716
Background And Aims: Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens...
6.
Zamor P, Russo M
Clin Liver Dis (Hoboken)
. 2019 Apr;
10(3):75-78.
PMID: 30992765
No abstract available.
7.
Norton B, Akiyama M, Zamor P, Litwin A
Infect Dis Clin North Am
. 2018 May;
32(2):347-370.
PMID: 29778260
Injection drug use is the most common transmission route for hepatitis C. High rates of infection are observed among individuals on opioid agonist therapy. Although people who inject drugs carry...
8.
Zamor P, Vierling J, Ghalib R, Luketic V, Ravendhran N, Balart L, et al.
Am J Gastroenterol
. 2018 Apr;
113(6):863-871.
PMID: 29695828
Objectives: Although direct-acting antiviral regimens have dramatically improved the treatment of hepatitis C virus (HCV) infection, there is some evidence that black race may be an independent predictor of treatment...
9.
Zamor P, deLemos A, Russo M
J Gastrointest Oncol
. 2017 May;
8(2):229-242.
PMID: 28480063
Chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) are associated with hepatic fibrosis and development of hepatocellular carcinoma (HCC). There are differences and variation with the incidence...
10.
Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han S, Thuluvath P, et al.
Ann Hepatol
. 2016 Oct;
15(6):834-845.
PMID: 27740516
Material And Methods: In this single-arm, open-label study, 246 patients received daclatasvir plus pegIFN alfa-2a and weight-based RBV. Patients with an extended rapid virologic response (eRVR; undetectable HCV-RNA at treatment...